Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

r at 5:45 pm CT on Monday, December 9, in the La Nouvelle Ballroom C.

The following posters will be presented by the investigators from The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital:

Activities Of Commonly Used Tyrosine Kinase Inhibitors Against Wild Type c-KIT And Potential Impact On Normal Hematopoiesis.  Session Name: Molecular Pharmacology, Drug Resistance: Poster III.  Presentation on Monday, December 9, 2013 from 6:00 - 8:00 pm in Hall E.

The Combination Of FLT3 Inhibition And Hypomethylation Confers Synergistic Antileukemic Effects On FLT3-ITD Positive AML Cell Lines And Primary Cells: Session Name: Acute Myeloid Leukemia: Therapy, excluding Transplantation: Poster III.  Presentation on Monday, December 9, 2013 from 6:00 - 8:00 pm in Hall E.

The abstracts and posters can be accessed on the ASH website at http://hematology.org.

Third Quarter Results
Revenues were $7.7 million and $4.3 million for the quarters ended September 30, 2013 and 2012, respectively.  The increase of $3.4 million was primarily due to acceleration in the recognition of license fee revenue related to the Company's collaboration with Astellas Pharma.  In March 2013, the Company received a notice of termination of the agreement from Astellas, which termination was effective September 2013. 

Research and development expenses were $4.5 million and $8.2 million for the quarters ended September 30, 2013 and 2012, respectively.  The decrease of $3.7 million was primarily due to lower quizartinib research and development expenses.  This resulted from a reduction in the number of patients being treated and followed in our Phase 2 clinical trial, in which enrollment was completed in late 2011. 

General and administrative expenses were
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... DryLet, LLC a biotechnology company providing ... animal waste reduction, bioremediation, wastewater treatment, aquaculture and ... plants and restaurant kitchen settings, announced today it ... 3-5 in Des Moines, Iowa. , ManureMagic™ was ... Journal article because of its industry-leading qualities and ...
(Date:5/28/2015)... 2015 BioNorth Texas (BioNorthTX), an ... the life sciences industry in northern region of ... at The Foundry in Dallas on April 27, ... together a broad spectrum of biotech professionals from ... early successes in partnering with key life sciences ...
(Date:5/28/2015)... , May 28, 2015  PDS Biotechnology Corp. ... immunotherapy treatment targeting HPV-16, has generated strong T-cell ... Currently, pre-cervical cancer is treated by surgical removal ... and effective non-surgical alternative. Results show that it ... to recognize, target, and kill precancerous and cancerous ...
(Date:5/28/2015)... 2015 RXi Pharmaceuticals Corporation (NASDAQ: RXII ... innovative therapeutics, primarily in the areas of dermatology and ... of 26 million units at a price to the ... approximately $10.4 million. Each unit consists of (i) one ... right to purchase 0.50 of a share of common ...
Breaking Biology Technology:DryLet to Showcase Patented ManureMagic™ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2BioNorthTX Holds Inaugural Board of Directors Meeting 2BioNorthTX Holds Inaugural Board of Directors Meeting 3PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3
... , LELYSTAD, ... biotechnology company focusing on protein mimicking,technology for the generation of ... Ph.D. as new Chief Executive Officer. , ... corporate functions and,the overall management and strategic direction of the ...
... , NANJING, China, Dec. ... (NYSE: SCR ), a leading pharmaceutical company,specializing ... proprietary pharmaceuticals in China, today announced that 105 of,its ... List,("NDRL"), which was issued by China,s Ministry of Human ...
... ... announced that he has joined Carolina Eyecare Physicians and has launched his ... Group. Dr. Solomon is a proven LASIK, lens implant, and cataract ... improving vision correction surgery. He is a member of Trusted LASIK ...
Cached Biology Technology:Dutch Biotech Company Pepscan Appoints New CEO 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 2Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 4Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 5Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 6
(Date:5/27/2015)... , May 27, 2015   ... medication safety systems and image documentation solutions ... of comprehensive, technologically-advanced automation solutions, is pleased ... integration. The Codonics® Safe Label System® (SLS), ... in conjunction with the Omnicell Anesthesia Workstation, ...
(Date:5/26/2015)... Research and Markets ( ... "Saudi Arabia Biometric Systems Market Forecast and ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The biometric systems market in ... to grow at over 22% CAGR through 2020 ... the surging demand for better biometric technologies in ...
(Date:5/25/2015)... May 25, 2015  Australia,s market for wearable technologies ... 2014 saw the advent of several trials and prototypes. ... 2015 is expected to ignite interest in wearables as ... Australia . This in turn will spur ... drive new partnerships amongst vendors and distributors. ...
Breaking Biology News(10 mins):Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4
... described in an advance online publication in Nature Genetics ... technique which, combined with other approaches, may explain 40 to ... just a few years, proposes the study,s lead investigator. This ... Seattle, will potentially allow clinicians to "lift the hood on ...
... seed to decide on the perfect time to germinate has ... biologists at The University of Nottingham have also discovered that ... important decision in the life cycle of plants when ... genetic mechanisms that plants use to detect and respond to ...
... This release is available in German . ... exciting experience," say Joachim Fischer and Tolga Ergin. For about ... Professor Martin Wegener at KIT,s Center for Functional Nanostructures (CFN) ... cloak to such an extent that it is also effective ...
Cached Biology News:New technique promises to 'lift the hood’ on autism 2New technique promises to 'lift the hood’ on autism 3New technique promises to 'lift the hood’ on autism 4Nottingham scientists reveal genetic 'wiring' of seeds 2Karlsruhe invisibility cloak: Disappearing visibly 2
... and analysis software for electrophysiology ... Contains powerful stimulus generation capabilities ... including automated waveform feature detection ... many electrophysiology specific functions including ...
A431 cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
A431 cells stimulated with EGF Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
... Certified USDA Research Registered OLAW Assured AAALAC ... AALAS Certified Technicians Documentation ... Upon Request Focus CRP is ... your custom immunology service needs. We ...
Biology Products: